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Abstract 
Leishmaniasis is one of the most neglected diseases in the World, according to 
the WHO, with new registered 300 000 cases every year. This disease affects mainly 
individuals from low income countries, where the access to diagnosis and treatment is 
very difficult. Besides this, the available chemotherapy is losing efficacy due to the 
emergence of resistant strains. So, there is a need for the development of new 
antileishmanial compounds and new strategies to refrain the impact of the disease. The 
proteins belonging to the ATP-binding cassette (ABC) family are transporters present in 
a wide variety of cells (from prokaryotes to eukaryotes) involved in the efflux of 
molecules. In many cases, these transporters become responsible for multidrug resistant 
(MDR) phenotypes and other resistance events in cells. One of the strategy to overcome 
this resistance is to use efflux pump inhibitors (EPI). The general goal of the present 
work is determine the action of efflux pumps in a context where macrophages from a 
cellular line (P388D1) get infected with more resistant Leishmania promastigotes from 
several species (Leishmania infantum, Leishmania amazonensis, Leishmania shawi and 
Leishmania guyanensis) and are exposed simultaneously to antileishmanial 
drugs/experimental compounds and efflux pump inhibitors. In this work, the first step 
was to differentiate different strains susceptible to Glucantime (GLUC), Miltefosine 
(MILT), ursolic acid (URS), chalcone-8 (CH8) and quercetine (QC). For the resistant 
strains obtained, the IC50 of the experimental compounds URS, CH8 and QC were then 
calculated. At last, in a context of macrophages infected with the different more 
resistant strains, it was evaluated the effect in their relative infection rate of a treatment 
consisting in experimental compounds combined with EPI, such as verapamil (VER), 
sodium orthovanadate (ORT) and Phe-Arg β-naphthylamide (PAβN). All the treatments 
could significantly reduce the relative infection rate of macrophages infected with the 
susceptible strains of Leishmania infantum, with the exception of the treatment with 
CH8 and VER in INF CH8 strain. For the several strains of Leishmania amazonensis, 
all treatments reduced the relative infection rate, with the exception for the treatments 
containing ORT, which seems to be harmless to this species. On the opposite side are 
the strains of Leishmania shawi and Leishmania guyanensis, where none of the 
treatments was able to reduce the relative infection rate of the macrophages. The EPI 
can effectively decrease the activity of efflux pumps activity and increase the efficacy 
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of antileishmanial drugs, and because of this, its use can be a possible alternative 
treatment for leishmaniasis. 
 
Key-words: Leishmaniasis, antileishmanial compounds, resistant parasites, 
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Resumo 
 
A leishmaniose é uma das doenças mais negligenciadas em todo o Mundo, de 
acordo com a OMS, sendo todos os anos registados 300 000 novos casos. A doença 
afecta, sobretudo, indivíduos de países em vias de desenvolvimento, onde o acesso ao 
diagnóstico e ao tratamento se torna extremamente complicado. Para além disso, a 
quimioterapia disponível apresenta uma eficácia progressivamente menor devido ao 
aparecimento de estirpes resistentes. Com tudo isto, torna-se imperativo o 
desenvolvimento de novos compostos antileishmania e de novas estratégias para 
diminuir o impacto da doença. As proteínas pertencentes à família ATP-binding cassette 
(ABC) são transportadores que se encontram presentes numa grande variedade de 
células (desde procariotas a eucariotas) e que são responsáveis pelo efluxo de 
moléculas. Muitas vezes, estes transportadores originam fenótipos resistentes, como é o 
caso do fenótipo multidrug resistant (MDR). Uma forma de ultrapassar esta resistência 
é recorrendo ao uso de inibidores destas bombas de efluxo. O principal objectivo deste 
trabalho é determinar a acção de bombas de efluxo num contexto em que macrófagos de 
uma linha celular (P388D1) são infectados com promastigotas mais resistentes 
pertences a diferentes espécies de Leishmania (Leishmania infantum, Leishmania 
amazonensis, Leishmania shawi e Leishmania guyanensis) e são expostos 
simultaneamente a fármacos/compostos experimentais antileishmania e inibidores das 
bombas de efluxo. No presente trabalho, o primeiro passo foi obter estirpes susceptíveis 
ao Glucantime (GLUC), à Miltefosina (MILT), ao ácido ursólico (URS), à chalcona-8 
(CH8) e à quercetine (QC). Para as estirpes que se conseguiram obter, foi determinado o 
valor de IC50 para os compostos experimentais URS, CH8 e QC. Por último, num 
contexto em que macrófagos foram infectados com diferentes estirpes mais resistentes, 
foi determinado o efeito na taxa de infecção relativa de um tratamento constituído por 
um composto antileishmania e por um inibidor das bombas de efluxo (EPI), como o 
verapamil (VER), o ortovanadato de sódio (ORT) e o Phe-Arg β-naftilamida (PaβN). 
Todos os tratamentos foram capazes de reduzir a taxa de infecção relativa de 
macrófagos infectados com as estirpes susceptíveis de Leishmania infantum, à excepção 
do tratamento com CH8 e VER feito à estirpe INF CH8. Para as diferentes estirpes de 
Leishmania amazonensis, todos os tratamentos apresentaram resultados positivos, à 
excepção daqueles que incluíam ORT, que parece ser inofensivo para esta espécie. No 
extremo oposto, encontram-se as estirpes de Leishmania shawi e Leishmania 
guyanensis, em que nenhum dos tratamentos reduziu a taxa de infecção. Os inibidores 
das bombas de efluxo (EPI) conseguem reduzir a actividade das bombas de efluxo e 
aumentar a eficácia dos fármacos antileishmania, e, por causa disso, o seu uso pode 
constituir um bom tratamento alternativo para a leishmaniose. 
  
Palavras-chave: Leishmaniose, compostos antileishmania, parasitas resistentes, 
bombas de efluxo, inibidores  
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I. Introduction 
 
1. Epidemiology of leishmaniasis and disease burden 
Leishmaniasis is one of the world’s most neglected tropical diseases (WHO. 
2010) and, considering both clinical manifestations of the disease, visceral and 
cutaneous,  the reported annual cases line up to 300 000 around the world. Of these, 
about 58 000 cases correspond to visceral leishmaniasis and 220 000 cases to the 
cutaneous forms, according to data available up to 2010. However, Alvar and 
colleagues refer estimations that reach almost the 2 million cases every year, including 
0.2 to 0.4 million of VL cases and 0.7 to 1.2 million of CL cases (Alvar et al. 2012). 
Considering VL, more than 90% of the reported cases occur in India, Bangladesh, South 
Sudan, Ethiopia and Brazil. On the other hand, CL cases are mainly distributed across 
Afghanistan, Iran, Pakistan, Saudi Arabia, Syria, Tunisia, Algeria, Ethiopia, Sudan, 
Peru, Colombia and Brazil. The concept of disability-adjusted life years (DALY) is a 
very useful index to assess the burden of any disease. In 2010, the estimation of DALY 
attributable to leishmaniasis was 3.3 million, which ranks leishmaniasis as the second 
most important tropical disease, only supplanted by the impact of malaria (Murray et al. 
2012).  
All these data concerning leishmaniasis must be faced with precaution, because 
it is very difficult to assess the real burden of the disease due to: (i) the focal distribution 
of the cases of leishmaniasis, which means that incidence is very heterogeneous within 
a territory, (ii) the variety of clinical manifestations, which leads to difficulties in 
diagnosis by medical staff and (iii) to the fact that there are different parasite species, 
different reservoir hosts and different vectors according to the considered region. But 
the main factor is the lack of available information concerning regional incidence and 
prevalence, DALYs, the mortality cases, as a direct result of poor organization of health 
services and the absence of surveillance programs (Bern et al. 2008; Singh et al. 2010). 
It is also well documented that conflict scenarios have an important role in the 
epidemiology of the disease, as it is the case of the Syrian Civil War and many other 
conflicts around Middle East (Jacobson. 2011). Multiple cutaneous leishmaniasis 
outbreaks have been happening around Syrian territory after the destruction of hospitals 
and other healthcare facilities  (Alasaad. 2013; Alawieh et al. 2014; Hayani et al. 2015; 
Inci et al. 2015). 
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Besides that, leishmaniasis is notifiable only in 33 countries of the 98 reported 
as endemic, which contributes to the current state of underreporting of cases as well 
(WHO. 2013). 
Desjeux points out some of the main factors leading to a worldwide increase of 
leishmaniasis incidence (Desjeux. 2001). On one hand, the expansion of deforestation 
and urbanization due to demographic pressure and migrations is bringing humans closer 
to the vectors and the reservoirs of Leishmania parasites. Consequently, the probability 
of any individual to get bitten by an infected phlebotomine will be substantially higher. 
One example of urbanization is the construction of dams, which always result in climate 
and vegetation modifications. The destruction of natural habitats has the potential to 
change the distribution of both sandfly (vector) and rodent (host) populations 
(Neouiminer. 1996). On the other hand, these processes have been occurring mainly in 
underdeveloped countries, which already have many problems in dealing with 
widespread poverty. Most of the times, poverty is associated with poor habitation, lack 
of sanitation and poor access to health care services. Along with that, the poor nutrition, 
the existence of other infectious diseases and the high cost of the available treatments 
for leishmaniasis also contributes to set up a scenario of increased susceptibility to 
leishmaniasis infection (Alvar, Yactayo, et al. 2006). 
 
1.1 Epidemiology of visceral leishmaniasis (VL) 
By the year of 2010, the World Health Organization (WHO) registered 
approximately 50 000 annual deaths due to the visceral form of leishmaniasis (WHO. 
2010) and the main victims were children with less than 15 years old (Savoia. 2015). 
Leishmania (Leishmania) donovani complex species are the responsible for this 
variant of the disease. L. donovani is associated with anthroponotic transmission of VL 
in the Old World, mostly rural and peridomestic foci in the Indian subcontinent, like 
Bihar state in India, Bangladesh, Bhutan and Nepal and foci in East Africa and 
Southwest Arabian Peninsula (these last in association with the zoonotic transmission of 
L.(L.) infantum). On the other hand, L. infantum involves peridomestic and rural foci as 
well, but in this case the transmission is zoonotic, occurring mainly in the 
Mediterranean basin, Central Asia (including Chinese regions), Saudi Arabia, Iran, Iraq 
and New World, more exactly in Latin America countries. It is possible to make a 
distinction between the cycle maintained between domestic dogs and vector and the 
cycle between vector and wild canines (foxes, for example). There is also evidence of 
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mother-to-child transmission of the parasite in humans, as some cases have already been 
reported (Ready. 2014). 
Although the lack of consensus on the subject, South-American L. (L.) chagasi 
species are recognized to be the same as Old World L. infantum species. Presumably, it 
was the Portuguese and Spanish colonization of South America, with the subsequent 
migration of infected domestic dogs, that was responsible for the introduction of this 
species into the New World (Lukes et al. 2007). 
Another important feature of this pathology is the occurrence of the post kala-
azar dermal leishmaniasis (PKDL) in VL patients (caused by L. donovani), especially in 
Southeast Asia foci (Salotra and Singh 2006). Nevertheless, this region, with 100 000 
VL cases estimated every year and 147 million people at risk, is achieving positive 
results in control and elimination of the disease: the number of cases have decreased by 
59% and mortality by 89%, although new foci have been detected (WHO. 2015). 
In Europe, leishmaniasis is a rare disease, with approximately seven hundred 
autochthonous VL cases every year, mainly in southern, western and in Balkan regions 
(Dujardin et al. 2008). VL is endemic in nine countries, including Portugal. According 
to Ready (2010), there is a risk of leishmaniasis emergence in Europe due to the 
introduction of exotic Leishmania species (through the migration of infected people 
from endemic areas outside Europe), the spread of Leishmania species to non-endemic 
areas where vectors of the parasite are present (mainly expansion northwards due to the 
movement of domestic dogs to endemic areas in a context of tourism and return to non-
endemic areas) and the increase in immunosuppressed people, such as HIV infected 
patients or people submitted to organ transplantation. According to the World Health 
Organization, 70% of adult VL cases in Southern Europe occur in HIV patients (WHO. 
2016b). HIV infection increases the risk of VL development, raises relapses and 
decreases therapeutic efficacy (Alvar et al. 2008). 
The global distribution of the disease can be assessed in Fig. 1. 
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Figure 1. Geographic distribution of visceral leishmaniasis (or Kala-
Azar) caused by L. infantum and L. donovan (red). Adapted from 
Chappuis et al. (2007)  
 
1.2 Epidemiology of cutaneous leishmaniasis (CL) and mucocutaneous 
leishmaniasis (ML) 
 As it happens with VL, there are distinct vectors, reservoirs and parasite species 
causing cutaneous leishmaniasis (CL) according to the geographic localization. 
However, children with less than fifteen years old are always more susceptible to the 
infection, regardless the considered region (Reithinger et al. 2007). 
Cl in Old World is caused by the following species: L. (L.) major, L. (L.) 
tropica, L. (L.) aethiopica and, in less extent, by L. donovani and L. infantum. CL 
caused by L. major is a rural zoonotic disease, with some wild rodents acting like a 
reservoir for the parasite, whereas L. tropica has an urban anthroponotic transmission 
cycle (Reithinger et al. 2007). There are registered CL cases caused by L. infantum, but 
they are inexpressive in comparison to the total amount of VL cases (Chaara et al. 
2014). L. aethiopica has a zoonotic cycle of transmission, where hyraxes are the 
reservoir (Negera et al. 2008). L. major is present in West Africa (Senegal), Middle East 
and India; L. tropica is found in the Middle East and Maghreb and L. aethiopica, as its 
name suggests, is present in Ethiopia and, with less expression, in Kenya (Pratlong et al. 
2009). 
In the New World, the most relevant species causing CL are those belonging to 
L. (L.) mexicana, L. (L.) amazonensis, L. (V.) braziliensis and L. (V.) guyanensis 
complexes. 
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The L. braziliensis complex includes the homonymous species, L. braziliensis, 
and other species, such as L. (V.) peruviana. The cycle of transmission of these parasites 
is mainly zoonotic, where rural and forest environments deserve special attention. The 
natural reservoir hosts of L. braziliensis are not completely elucidated, but it is thought 
that small forest rodents and domestic animals (dogs, horses, donkeys) may play an 
important role in parasite epidemiology (Shaw. 2002; Gontijo and De Carvalho 2003). 
Some infected dogs have been detected, but probably they are not the main reservoir of 
the parasite, due to their low reservoir competence (Dantas-Torres. 2007). This species 
are distributed all across Central and South America. 
 L. guyanensis complex includes L. guyanensis and L. shawi. Edentate and 
marsupials are the natural reservoir of L. guyanensis, whereas monkeys and sloths 
maintain the cycle of transmission of L. shawi.  L. guyanensis is mainly distributed 
throughout the north of the Amazon river, including some Colombia and Ecuador 
regions and L. shawi can be found south of the Amazon river (Shaw. 2002). 
 L. mexicana and L. amazonensis have some rodent species as their main hosts. L. 
amazonensis is associated with zoonotic cycles in forest environments and it is present 
in South America. L. mexicana is distributed throughout Central America and 
Venezuela (Shaw. 2002).  
 The overall geographic distribution of CL across the world can be consulted in 
Fig. 2. 
 
Figure 2. Endemic areas for cutaneous leishmaniasis (green). Adapted from 
Reithinger et al. (2007) 
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The main etiological agent of mucocutaneous leishmaniasis (ML) is L. 
braziliensis. However, some few cases can be caused by L. (V.) panamensis, especially 
in jungle areas or lands that were deforested. This former species has the sloth as 
reservoir host and occurs in Central America and Colombia (WHO. 2010) 
 
2. Clinical presentations of leishmaniasis 
 
2.1 Visceral leishmaniasis 
Manifestations of visceral leishmaniasis (VL) or Kala-azar usually last for 
months or years. Leishmania parasites mainly infect cells that belong to the 
mononuclear phagocyte system. Some associated symptoms are fever, cough, diarrhea, 
weight loss, lymphadenopathy and, most important, a progressive hepatosplenomegaly 
and bone marrow suppression. Development of these symptoms are followed by 
pancytopenia and immune-suppression and, ultimately, death overcome in two years 
after infection if no treatment is administered (Kevric et al. 2015) 
 
2.2 Cutaneous leishmaniasis 
Usually, the incubation period of cutaneous leishmaniasis can take days to 
months. The clinical manifestations always begin with a small papule that can ulcerate 
in cases of infection by L. major or New World cutaneous species, or, alternatively, can 
evolve to nodules or go through a process of hyperkeratosis (dry lesions) (Bailey and 
Lockwood. 2007). Nodular lesions usually appear in infections by L. aethiopica and by 
the species of the L. donovani complex, whereas hyperkeratotic lesions occur in the 
context of L. tropica infection. These lesions imply pain, pruritus and, in some cases, 
secondary bacterial infections.  Another variant of acute CL includes local 
dissemination of parasites or antigens to the surrounding regions of the original lesion, 
in particular through the lymphatic vessels.  
 The disease acquires a wider disseminated character when ten or more lesions 
occur in two or more nonadjacent areas of the body (Bailey and Lockwood. 2007). This 
type of cases is caused by New World species and is very rare.  
Diffuse CL consists in the development of nonulcerating lesions followed by 
dissemination to the face and exterior surfaces of the limbs and the eventuall destruction 
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of deeper tissues. This clinical form of the disease it is associated with L. amazonensis 
and L. aethiopica infections (Herwaldt, 1999). 
 
2.3 Mucocutaneous leishmaniasis 
MCL is initially characterized by the development of local CL lesions and the 
appearance of parasites metastasis. In the following stage, the parasites disseminate 
through hematogenous or lymphatic spread and invade the mucocutaneous tissue, such 
as the nose, the mouth and the noropharyngeal mucosa. This form of the disease can last 
months to several years. The chronic symptoms consist in the progressive destruction of 
the noropharyngeal mucosa, which leads to the disfiguration of the affected individual 
(Mcgwire and Satoskar. 2014). Along with this, the respiratory function and the 
nutrition are hampered. 
 
3. The phlebotomine vector 
 Phlebotomines are insects included in Order Diptera, family Psychodidae and 
subfamily Phlebotominae. Until now, the blood-feeding phlebotomine females are the 
only proven natural vectors of Leishmania parasites (Ready. 2013). There is not a 
consensus about the exact number of sandfly species that exist in the world. For 
example, Ready cites approximately nine hundred different species, seventy of which 
implicated in leishmaniasis transmission (Ready. 2013). Marolli and collaborators refer 
eight hundred species and ninety eight species involved (or suspected to be involved) in 
leishmaniasis transmission (Maroli et al. 2013). Of these, there are forty-two Old-World 
phlebotomine species, more specifically those that belong to Phlebotumus genus, and 
there are fifty-six New-World species, belonging to Lutzomyia genus. However, looking 
to older articles, the numbers that can be found may be very different from these one: 
Killick-Kendrick points out eighty-one species of sandflies and nineteen species proven 
vectors of Leishmania parasites (Killick-Kendrick. 1990). This lead to the conclusion 
that information can vary according to the taxonomic classification that is used.  
In Portugal, five different phlebotomine species are present: Phlebotomus 
(Larrousius) perniciosus Newstead, 1911, P. (L.) ariasi Tonoir, 1921, P. 
(Paraphlebotumus) sergenti Parrot, 1917, P. papatasi Scopoli, 1786 and Sergentomyia 
(Sergentomyia) minuta Rondani, 1843 (Branco et al. 2013). However, only two species, 
P. perniciosus and P. ariasi,  have been implicated in leishmaniasis transmission, more 
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precisely in the transmission of L. infantum (Pires. 1984 cited by Campino and Maia. 
2010). P. sergenti and P. papatasi, vectors of L. tropica and L. major, respectively, 
have been detected in Portuguese territory, in the southern region of Algarve (Maia et al. 
2009), but there are not reported autochthonous cases of leishmaniasis caused by the 
referred parasites. Several studies have been demonstrating the presence of sand fly 
species all across the country, where some foci, due to their association with canine and 
human leishmaniasis, deserve special attention: Alto-Douro (Afonso et al. 2007), 
Lisbon Metropolitan Region (Afonso et al. 2005), Évora region (Afonso and Semião-
Santos 2004) and Algarve region (Maia et al. 2009). 
 
4. Parasite life cycle 
The life cycle of parasites belonging to Leishmania genus includes two different 
developmental stages (dimorphic life cycle): one that occurs inside a phlebotomine 
vector; another that happens inside a vertebrate host, which can be a human, a dog, a 
rodent, or another species. The complete schematic of the life cycle can be assessed in 
Fig. 3. 
 The parasite itself can assume two distinct forms: a promastigote stage, a motile, 
elongated form with 5 μm in diameter; an amastigote stage, a non-flagellated, spherical 
form with 2.5 to 5 μm in diameter. 
 
Figure 3. Schematic life cycle of the parasites belonging to Leishmania genus. Grey area: 
development in sand fly vector. White area: development in vertebrate mammalian host. 
Adapted from Gossage et al. (2003). 
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4.1 Vector stage 
During its life cycle, the parasite thrives in diverse environments with different 
conditions of temperature, pH and others. An essential feature of this cycle happens 
when a female phlebotomine takes a blood meal in the infected vertebrate host through 
pool feeding. This process involves the cutting of the host skin with the mouthparts of 
phlebotomine, followed by feeding from the resulting blood pool. Together with the 
blood meal, aflagellated amastigotes are also ingested; these forms will divide in the 
midgut of the vector, experiencing a colder and more alkaline environment than the 
environment provided by the vertebrate host. Leishmania parasites increase the 
expression of surface molecules, such as the glycoconjugates lipophosphoglycan (LPG) 
and metalloprotease gp63, to enable the survival in the hydrolytic environment of the 
gut (Cunningham. 2002). Simultaneously with division, amastigotes are converted in 
procyclic promastigotes, little motile parasites. This blood meal phase occur within the 
peritrophic membrane, a chitinous matrix secreted by the epithelial cells of the gut 
(Bates. 2007). One of the criteria to differentiate the subgenus Leishmania and the 
subgenus Viannia is to consider the specific site that parasite occupy in the sandfly gut: 
parasites of subgenus Leishmania are present in the midgut and foregut of the vector, 
whereas parasites of subgenus Viannia in the midgut, the foregut and also the hindgut 
(Gossage et al. 2003). After some days post-infection and before the complete digestion 
of the blood meal, the parasites convert into nectonomads, a migratory form, and 
accumulate in the anterior abdominal midgut, while producing and secreting 
promastigote-secretory gel (PSG) (Bates. 2007). This accumulation ultimately leads to 
the destruction of the peritrophic matrix and to the following release of blood medium. 
Promastigotes then migrate to thoracic midgut and to stomodeal valve, where they 
originate leptonomads, shorter forms that replicate and later convert into metacyclic 
promastigotes (high motile forms), the unique infective form to the vertebrate host; 
some of the migratory nectonomads also convert into a shorter and circular form called 
haptomonads (Schlein. 1993).  
 There are two alternate views on the transmission of metacyclic promastigotes to 
the vertebrate host: inoculation versus regurgitation. Inoculation theory says that only 
the metacyclic promastigotes present in sandfly proboscis are transmitted to the 
vertebrate host during the bite. On the other hand, the “blocked fly hypothesis” claim 
that the obstruction and damage of stomodeal valve lead to the reflux of parasites during 
the bloodmeal and consequent infection of the host (Bates. 2007). There is no consensus 
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on the subject, but it is thought that the two processes may occur simultaneously or 
independently according to the Leishmania species or the sandfly species considered. 
 
4.2 Vertebrate stage 
As a female phlebotomine takes a blood meal in the vertebrate host, 
simultaneously inoculates metacyclic promastigotes into the skin, which promptly elicit 
the immune response of the victims. Polimorphonuclear cells (PMN) and mononuclear 
phagocytic cells are the first to act in the region of the bite, which favors the progression 
of infection. Neutrophils, macrophages and dendritic cells are phagocytic cells able to 
internalize the metacyclic promastigotes. 
As Laskay and collaborators refer (Laskay et al. 2003), neutrophils can be 
considered «Trojan horses», because they indirectly allow the entrance of 
microorganisms into the macrophages. For example, it has been proved that the species 
L. major, L. aethiopica and L. donovani have a marked chemotactic effect on human 
PMN, but not in macrophages and Natural killer (NK) cells (Van Zandbergen et al. 
2002). This effect is achieved through the production of a chemotactic factor by the 
parasites and, simultaneously, through the induction of interleukin (IL)-8 (a chemokine) 
production by PMN. Neutrophil apoptosis and subsequent ingestion by macrophages are 
natural mechanisms of the inflammatory response (Witko-Sarsat et al. 2000). It follows 
that Leishmania infected neutrophils are ingested by macrophages, thus favoring 
parasite survival. First, because the macrophage receptors are not involved in this 
process, the pathways that depend on these interactions leading to pathogen elimination 
are not activated. On the other hand, the phagocytosis of apoptotic neutrophil will have 
an immunosuppressive effect in the macrophage (Sun and Shi. 2001), contributing to 
proliferation of the parasite within this cell. Besides this, Leishmania parasites have the 
capacity to interfere with receptor responsiveness in macrophages, such as the Toll-like 
receptor and CD40 (Bhardwaj et al. 2010). 
In the intracellular environment of macrophages, the parasitic form (whether it is 
a metacyclic promastigote or an amastigote) will initially thrive in the parasitophorous 
vacuole. This compartment later fuses with early and late endosomes and lysosomes, a 
process that originates a phagolysosome with very acidic conditions and high 
temperature (Liévin-Le Moal and Loiseau. 2016). Then, the metacyclic promastigotes 
convert into non-motile amastigotes. During the intracellular stage, the parasite 
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modulates the host cell pathways and subvert its defense mechanisms against 
pathogens, such is the case of oxidative damage, to ensure its survival and replication 
(Moradin and Descoteaux. 2012). This stage ends with the release of the amastigotes to 
the extracellular space, either by cell lysis due to excessive parasite replication or to the 
active manipulation of the exocytic pathways of the host cell by the parasite (Rittig and 
Bogdan. 2000). From here, amastigotes can infect other cells in different organs (skin or 
deeper tissues, such as the liver and the spleen), depending on parasite species and host 
susceptibility. Amastigotes are then available in the bloodstream and, if a phlebotomine 
takes a bloodmeal in the infected individual, the parasite will be transmitted to the 
vector and therefore the cycle will continue. 
 
 
5. Treatment of leishmaniasis 
 
In general, the main problems arising from the chemotherapy application in 
clinical cases are related with high toxicity and subsequent adverse reactions, long 
duration of treatment leading to a decrease of compliance and to the fact that most drugs 
do not eliminate completely the parasite from the organism (Menezes et al. 2015).  
 
5.1 Treatment of visceral leishmaniasis 
 Pentavalent antimonials have been the standard first-line medicines for the 
treatment of visceral leishmaniasis for decades. Sodium stibogluconate  (Pentostam®) 
and meglumine antimoniate (Glucantime®) are the two chemically similar forms used 
in clinical field against a variety of Leishmania species (Piscopo and Mallia Azzopardi. 
2007). 
Thiol redox homeostasis is absolutely vital to the survival of parasite, because it 
has an impact on parasite response against chemical and oxidative stress (Baiocco et al. 
2009). Trypanothione (T(SH)2), an enzyme only present in trypanosomatids, is the 
mainstay of this system. Its production requires the synthesis of glutathione (GSH) and 
spermidine (Spd) and the further conjugation of these metabolites catalysed by 
trypanothione synthetase (TryS), as it is visible in Fig. 4 (Leroux and Krauth-Siegel. 
2015). 
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Figure 4. – Simplified overview of trypanothione 
synthesis. Abbreviations: GSH, glutathione; Spd, 
spermidine; Gsp, glutathionylspermidine; TryS, 
trypanothione synthetase; T(SH)2, trypanothione 
(reduced form). 
 
Trypanothione reductase (TR) is responsible for linking the NADPH based 
metabolism to thiol based metabolism, as it catalyses the reduction of trypanothione 
using a NADPH molecule (Fig.5). 
 
 
 
 
 
 
 
 
 
Figure 5. – Activity of trypanothione reductase.  In the presence of  NADPH, trypanothione 
reductase  reduced the dissuphide bound of trypanothione originiating of the reduce form of 
trypanothione. Abbreviations: TS2, trypanothione disulphide; TR, trypanothione reductase; 
T(SH)2, trypanothione (reduced form); NADP+,  nicotinamide adenine dinucleotide 
phosphate; NADPH, reduced form of NADP+. 
 
Although their profuse application, the molecular and cellular mechanisms of 
action of pentavalent antimonials are not completely unveiled and, consequently there 
are different theories trying to explain the leishmanicidal action of this class of 
compounds. Pentavalent antimonials are pro-drugs, which means they need to be 
reduced to trivalent form to be activated. Thiol-dependant reductase (TDR1) is an 
enzyme present in higher concentrations in the amastigote stage of Leishmania and have 
TryS 
GSH Spd 
Gsp 
 
GSH 
T(SH)2 
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TR 
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the capacity to convert Sb(V) in its reduced form, Sb(III) (Denton et al. 2004). This is 
probably the reason why amastigotes are more susceptible to antimonials action than 
promastigotes. 
It is thought that the reduced form of pentavalent antimonials, or Sb (III), can 
interfere with host immune activation, inducing oxidative and nitrosative stress in 
macrophages. On the other hand, these drugs can affect trypanothione metabolism of the 
parasite itself through many ways. First, they can stimulate the rapid efflux of 
intracellular trypanothione and glutathione; second, they inhibit trypanothione reductase 
action, which causes the accumulation of disulfide forms of both trypanothione and 
glutathione. This ultimately compromises the thiol redox potential of parasite, leading to 
its death (Leroux and Krauth-Siegel. 2015; Wyllie et al. 2004). Since molecules like 
trypanothione reductase and trypanothione are specific for trypanosomatids, they can be 
good targets to the development of new chemotherapeutic agents. 
These compounds are administered through intramuscular or intravenousl 
injections and have been associated with severe adverse reactions like anorexia, 
vomiting, nausea, abdominal pain, malaise, myalgia, headache and lethargy (WHO, 
2010). Although the easy availability and low cost of these drugs, the length of 
treatment is often a problem. Jointly with the generally decrease of efficacy, mainly due 
to emergence of parasitic resistant-strains, these factors restrain its use in the clinical 
field. Resistance to treatment has been documented all around the world, particularly in 
Indian subcontinent: in hyper endemic northern region of Bihar it was registered a 
pentavalent antimony resistance of 65% in a group of treated patients (Sundar et al. 
2000). 
 Amphotericin B (deoxycholate) is a polyene antibiotic that originally was 
exclusively used in the treatment of fungal infections (Hamill, 2013). However, this 
drug also have efficacy against a variety of other micro-organisms, like Leishmania and 
Trypanosoma cruzi (Croft et al. 2006). It has been a second-line drug for the treatment 
of visceral leishmaniasis, especially in antimony-resistant cases. However, in India, it is 
included in first-line drugs, due to widespread resistance to pentavalent antimonials 
(Croft and Olliaro, 2011). The compound binds ergosterol present in cell membranes, 
which consequently leads to the formation of membrane channels and ultimately cell 
disruption (Croft et al. 2006). The high toxicity and adverse reactions associated with 
the application of this drug in clinical cases, like fever, rigor, chills, thrombophlebitis of 
the injected vein and nephrotoxicity (WHO, 2010) has been limiting its use. To 
   
14 
 
overcome these obstacles, new formulations of the drug have been developed. 
Liposomal amphotericin B seems to be a viable alternative because it can decrease the 
adverse effects associated with drug administration and, simultaneously, improve drug 
pharmakinetics and bioavailability (Hamill, 2013), although it has an high cost. 
Pentamidine (1,5-bis(4-amidinophenoxy)pentane) is an antimicrobial drug that is 
included in second-line treatment of visceral leishmaniasis. Pentamidine and its 
analogues have been used for nearly sixty decades in the treatment of various diseases 
besides leishmaniasis, like malaria, human african trypanosomiasis and Pneumocystis 
carinii pneumonia (Porcheddu et al. 2012). Its mechanism of action is not well 
understood, but, as trypanosomes have the capacity of actively internalize pentamidine, 
it is thought that the drug could affect DNA biosynthesis of parasite (Sands et al. 1985). 
Intramuscularly injection, secondary effects like diabetes mellitus, hypoglucaemia, 
shock, miocardis nephrotoxicity  and low efficacy do not encourage a more intensive 
use of the drug (WHO 2010). 
Miltefosine was registered for commercial use in 2002 and at the moment is the 
only oral drug available for the treatment of both visceral and cutaneous leishmaniasis. 
Miltefosine (or hexadecylphosphocholine) is a compound belonging to 
alkylphospholipids family that was initially used in the treatment of tumours. Its 
mechanism of action consists in the induction of apoptosis-like cell death and 
dysregulation of lipid metabolism (Dorlo et al. 2012a). Rakotomonga et colleagues 
achieved evidence of alterations in phospholipidic membrane of the L. donovani 
parasites after miltefosine exposure, specifically “intromission” of molecules of 
hexadecylphosphocholine in phospholipid monolayer and decrease in 
phospatidylcholine content simultaneously with increase of phosphatidylethanolamine 
content (Rakotomanga et al. 2007). 
  
5.2 Treatment of cutaneous leishmaniasis 
Many of the chemotherapeutic agents available in the treatment of visceral 
leishmaniasis have application in the treatment of the cutaneous form of leishmaniasis. 
The disease is usually self-limiting, not fatal and therefore the application of therapy is 
mainly local. 
 Pentavalent antimonials are used in CL treatment through intralesionally 
administration. Their efficacy in not completely proven yet, as there is a significant 
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variation in clinical response between the different Leishmania species. Amphotericin B 
deoxycholate is a second-line drug in CL treatment, but the cost, the need for parental 
administration and the toxicity associated hampers its use (Alvar and Croft, et al. 2006). 
Miltefosine is also used in Cl treatment, however its use is not effective in all relevant 
Leishmania species. For example, Soto and colleagues showed that this drug is only 
active in the treatment of CL caused by L. panamensis and not CL caused by L. 
braziliensis (Soto et al. 2004). Paromomycin is present in various topical formulations, 
being a useful drug against both old and new cutaneous leishmaniasis. WHO 
recommends a topic containing 15% paromomycin/12% methylbenzethonium chloride 
for the treatment of Cl caused by L. major, L. tropica, L. aethiopica, L. infantum and all 
forms of New World CL (WHO, 2010). 
 
5.3 Development of new potential chemotherapeutic agents 
Flavonoids (included in the group of polyphenols) are a class of secondary 
metabolites mainly extracted from plants, like fruits, vegetables, nuts, stems, flowers 
and also wine and tea, being part of the daily diet of the human being (Scalbert and 
Williamson 2000). 
Chalcones are members of this group and their relatively simple structure and 
preparation allows the synthesis of derivatives with different biological functions 
(Passalacqua et al. 2015). Some of these derivatives may present relevant leishmanicidal 
activity, which justifies their study and development.  
 The standard structure of chalcones comprises an open chain with two aryl rings 
(an aryl ring is a substituent group made of an aromatic ring or one of its derivatives) 
connected by an α,β – unsaturated carbonyl structure, as it is visible in Fig.6 (Roussaki 
et al. 2013). 
 
 
 
 
 
 
Figure 6. General structure of Chalcones, 
with two aryl rings: A and B. From 
https://www.emolecules.com/ 
A B 
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There is some evidence that chalcones and their derivatives can have an 
important role in the fighting against Leishmania species. Litochalcone, for example, 
inhibit in vitro growth of L. major and L. donovani promastigotes and kills L. major 
amastigotes (Zhai et al. 1995). This happens because litochalcone destroy the parasitic 
mithocondria, more specifically, the respiratory chain of the parasite, thus impairing its 
respiratory activity and its survival. Another derivative of chalcone, 2’,6’-DIhydroxy-4’-
methoxychalcone (DMC) have shown selective in vitro activity against promastigote 
and amastigote forms of L. amazonensis and no activity against macrophages (Torres-
Santos et al. 1999). Chalcones (1-4), derivatives of the general structure of chalcones, 
reduce significantly the parasite burden of L. braziliensis in macrophages, without 
having a cytotoxic effect on these cells (de Mello et al. 2014). 
Quercetin, a plant-dietary flavonoid, is another compound that has shown 
interesting anti-leihsmanial activity. This compound is a flavonol, which is a class of 
compounds that share a 3-hydroxyflavone backbone (Fig.7). 
 
Figure 7. Structure of quercetin. From 
https://www.emolecules.com/ 
 
Quercetin can impair in vitro growth of both L. donovani promastigotes and 
amastigotes, according to Mittra and colaborators (Mittra et al. 2000). They have 
demonstrated that quercetin and luteolin (another flavonoid) interphere with Leishmania 
topoisomerases activity, which led to significant promastigote apoptosis and reduction 
of parasite burden in the spleen of hamsters. Besides this, quercetin is also implied in 
the inhibition of L. amazonensis arginase (Da Silva et al. 2012). Arginase is an enzyme 
involved in the catalisation of the final step of urea cycle and quercetin can compete 
with L-arginine and Mn2+, substrate and cofactor, to the binding site of this enzyme. 
Iron is essential for Leishmania survival inside macrophage phagolysosomes, 
because the parasite can’t synthetize the heme group, so it needs to use the iron of the 
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host. Quercitin is a lipophilic metal chelator, which means that it binds to metal ions 
through hydrogen binding and can cross the cellular plasma membrane. Sen and 
collaborators provided a combined treatment of quercetin and serum albumin to 
hamsters infected with L. donovani, which led to significant reduction of splenic 
parasite burden (Sen et al. 2008). This happens due to interpherence in parasite iron 
metabolism, more specifically the reduction of ribonucleotide reductase activity in 
phagolysosomes, which is an iron-dependent enzyme involved in DNA synthesis. 
Ursolic acid is a triterpene that is present in food and in many natural plants. 
This pentacyclic triterpenoid, which structure is represented in Fig.8, has some 
therapeutical application, for example, in the apoptosis of tumor cells (Wang et al. 
2011). 
  
 
Figure 8. Structure of ursolic acid. From 
https://www.emolecules.com/ 
 
 In addition, other effects of this compound have been documented, with 
particular attention to the antiprotozoal ones. Ursolic acid extracted from Baccharis 
dracunculifolia, a plant belonging to Asteraceae family, has shown interesting 
leishmanicidal activity (IC50 = 3.7 μg.ml-1) against the promastigote forms of L. 
donovani (Filho et al. 2009). Passero and coworkers have demonstrated that a fraction 
containing oleanolic and ursolic acid significantly decreases the growth rate of L. 
amazonensis and L. braziliensis amastigotes and decreases the infection rate of J774 
macrophages, due to the increase in nitric oxide production (Passero et al. 2011). These 
antileishmanial effects were accompanied by a lack of citotoxicity in macrophage cells. 
Other in vivo studies corroborate these in vitro findings, as it is the case of Yamamoto et 
al. (2014). In this work, BALB/c mice infected with L. amazonensis were treated with a 
triterpenic fraction composed by oleanolic and ursolic acid and the results were 
comparable to those obtained when the mice were treated with amphotecin B. The same 
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group have proved that ursolic acid alone is capable of destroy L. amazonensis 
promastigotes with a dose comparable to miltefosine, while lacking toxicity towards 
peritoneal macrophages of BALB /c mice (Yamamoto et al. 2015). According to the 
authors, the promastigotes were killed by programmed cell death related with 
mitochondrial activity and the amastigotes due to the increase in nitric oxide production 
by macrophages. 
 
6. The role of ABC transporters in drug resistance 
 At cellular level, any molecule, ion, drug or virus needs to cross biological 
membranes, with the ultimate goal of ensuring the survival of any cell or, if it’s the case, 
the survival of some pathogenic micro-organism. One of the main class of proteins 
involved in the translocation of particles across membranes is the ATP-binding cassette 
transporters (ABC transporters) superfamily, which is widely represented in both 
prokaryote and eukaryote domains. In prokaryotes, these transporters are responsible for 
the import and extrusion of substrates, while in eukaryotes cells the ABC transporters 
only participate in extrusion (Sauvage et al. 2009). For example, in human cells, these 
proteins are involved in transportation of endogenous substrates, as inorganic anions, 
metal ions, peptides, amino acids, sugars and a large number of hydrophobic or 
cytotoxic compounds and metabolites across the plasma membrane (Vasiliou et al. 
2009). 
 Most of eukaryote ABC proteins are a polypeptidic chain composed of four 
domains: two hydrophobic transmembrane domains (TMD), responsible for substrate 
translocation, and two nucleotide-binding domains (NBD), involved in ATP binding and 
hydrolysis (usually represented by TMD2-NBD2) (Fig.9). The nucleotide-binding 
domains are more conserved throughout the species, due to the presence of three 
consensus regions: Walker motifs A and B (involved in magnesium-ATP binding) and 
an ABC transporter signature, the “C motif”, that is located between the two Walker 
motifs and has unknown function (Pérez-Victoria et al. 2001) 
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Figure 9. ABC transporters involved in import (A) and export (B) of substrates. 
TMD represents the transmembrane domains; NBD, nucleotide binding domains, 
bind the adenosine-triphosphate (ATP) molecules. The resulting hydrolysis of ATP 
provides the necessary energy for the translocation of substrates across the plasma 
membrane, with the subsequent production of adenosine diphosphate (ADP) and 
inorganic phosphate (Pi). Adapted from Locher (2009) 
 
The genome of Leishmania spp contains 42 genes belonging to ABC genes 
family, but only 32 encode ABC transporters proteins. It is the largest ABC data set 
among protozoans (Sauvage et al. 2009). The ABC transporters superfamily are divided 
into 8 subfamilies, according to gene structure similarity and NBD homology. Every 
single one of the 8 major subfamilies that can be encountered in eukaryotic cells are 
present in Leishmania genome (from ABCA to ABCG subfamily) (Leprohon et al. 
2006). 
The first subfamily is ABCA, which comprises ten genes of the Leishmania 
genome. This set of genes encodes ABC functional transporters with TMD2-NBD2 
topology. The first member of this subfamily to be discovered was LtrABC1.1 and it is 
involved in lipid movements across the plasma membrane and in vesicle trafficking; 
transfected L. tropica promastigotes overexpressing this transporter showed a decrease 
in infectivity of macrophages (Parodi-Talice et al. 2003). The other ABCA transporter 
characterised, LtrABCA2, seems to have the same functions of LtrABC1.1 (Araújo-
Santos et al. 2005), which means that none of these proteins is related to drug resistance 
in Leishmania spp. 
The second subfamily is ABCB and the Leishmania genome contains four genes 
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belonging to this group. The expression of the P-glycoprotein transporters in 
mammalian cells confers a multi-drug resistance (MDR) phenotype, specifically in 
cancer cells. In Leishmania, some P-glycoprotein-like transporters are expressed. Two 
of these genes encode full-transporters with TMD2-NBD2 topology that are present in 
subcellular locations: ABCB4 (mdr1 homologous) and ABCB2 (mdr2 homologous). 
Henderson and coworkers first demonstrated that amplification of ldmdr1 gene in L. 
donovani was responsible for a drug-resistant phenotype (Henderson et al. 1992a). 
Later, it was found out that the homologous of this gene in Leishmania tropica was 
located in extrachromosomal circular DNA: expression of this P-glycoprotein was 
increased in parasites resistant to daunomycin (Chiquero et al. 1998). Since then, many 
works have been clarifying the association between these Pgp-homologues and 
resistance to various drugs in some Leishmania species, such as vinblastine (Dodge et 
al. 2004), doxorubicin and actinomycin D (Katakura et al. 1999) and, more important 
due to their application in the clinical field, miltefosine (Pérez-Victoria et al. 2001). On 
the other hand, the ABCB2 (or MDR2) transporter is associated with resistance to 5-
fluoroacil (a drug used in cancer chemotherapy) in wild-type promastigotes belonging 
to L. amazonensis species (Katakura et al. 2004a). 
The third subfamily, ABCC,  is also represented in Leishmania genome with 
eight members. Six proteins encoded by these genes are homologous to the members of 
multidrug resistance-associated proteins (MRP) found in mammalian cells. The gene 
LtPGPA (or ABCC3) that encodes P-glycoprotein A (a MRPA homologous), or simply 
PGPA, was first discovered in H-circles (extrachromosomal DNA) of methotrexate-
resistant parasites belonging to  L. tarentolae species (Ouellette et al. 1990). In fact, this 
transporter has an important role in parasite resistance to compounds containing heavy 
metals, such as arsenite and antimony (Callahan and Beverley. 1991; Singh et al. 
2014).This protein is positioned in membranes next to the flagellar pocket of the 
parasite and acts through the sequestration of metal-thiol conjugates (containing 
glutathione or trypanothione) into a intracellular vesicle, thereby avoiding toxic effects 
(Légaré et al. 2001). Another transporter belonging to this subfamily is pentamidine 
resistance protein 1 (PRP1) and, as the name reveals, has been associated with 
resistance to pentamidine and trivalent antimonials in both L. major promastigote and 
amastigote forms (Coelho et al. 2003, 2007). This transporter is only present in 
Leishmania genus and not in other trypanosomatids, such as those included in 
Trypanosoma genus (Leprohon et al. 2006). However, the role of this protein in 
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resistance seems to be restricted to some Leishmania species because it has been proved 
that laboratory-induced resistance does not increase PRP1 expression in Leishmania 
amazonensis promastigotes (Coelho et al. 2008). 
The ABCG subfamily has six genes in Leishmania genome, all encoding half-
full transporters, i.e., proteins with NDB-TMD topology. These proteins require 
dimerization to assemble a functional protein that can be a homo- or a heterodimer.  The 
main proteins of this subfamily are ABCG6 homologues, like LiABCG6 and 
LdABCG6, and ABCG4 (LiABCG4). Their function is related with lipid transport 
across membranes, more specifically short-chain phospholipids analogues, and with 
extrusion of multiple compounds, such as alkyl-phospholipids (miltefosine, perifosine, 
edelfosine), sitamaquine, camptothecin. (Castanys-Muñoz et al. 2007; BoseDasgupta et 
al. 2008; Castanys-Muñoz et al. 2008). To accomplish this, the position of these proteins 
in plasma membrane and flagellar pocket region are essential factors. 
Until this moment, proteins encoded by genes of ABCD, ABCE, ABCF e ABCH 
subfamilies are not characterised in Leishmania spp, although there are ten genes 
included in these groups. Another four ABC genes not included in any subfamily are 
present in the parasite genome (Sauvage et al. 2009). 
 
7. Modulation of ABC transporters in Leishmania spp 
The failure of traditional chemotherapeutic agents against the clinical forms of 
leishmaniasis urges the need of alternative strategies in the treatment of the disease. The 
use of drugs or new leishmanicidal compounds associated with ABC transporter 
modulators, mainly inhibitors, is a promising way to accomplish that objective. The 
main modulators are divided in various groups: calcium channel blockers, flavonoids, 
sesquiterpenes and pyridine analogues (Pradines et al. 2005).  
The calcium channel blockers, as the name implies, act through the impairment 
of the activity of efflux pumps relying on calcium pathways. For example, verapamil 
(VER), widely used in the treatment of heart diseases, is a well-known inhibitor of the 
P-glycoprotein activity in cells with MDR phenotype (Wu et al. 2014), specifically in 
tumour cells ( Tsuruo et al. 1981; Rogan et al. 1984). Neal and co-workers were the first 
to explore the use of verapamil in the reversal of drug-resistance phenotypes in 
trypanosomatids, more specifically in nifurtimox-resistant T. cruzi and antimony-
resistant L. donovani (Neal et al. 1989). The energy-dependent efflux of pirarubicin, a 
drug that inhibits DNA replication, is inhibited by verapamil in L. mexicana, L. 
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guyanensis and L. braziliensis promastigotes (Essodaïgui et al. 1999). Besides this, 
many phenothiazine derivatives are included in calcium channel blockers. 
Phenothiazine derivatives inhibits the binding of calcium to calmodulin (transport 
protein) and thus affect the efflux pump activity (Grácio et al. 2003). These compounds 
have antimicrobial activity and successfully revert both multi-drug resistant 
Mycobacterium tuberculosis (MDRTB) and methicillin-resistant Staphylococcus aureus 
(MRSA) phenotypes (Amaral et al. 2004) and have antimalarial activity and can revert 
drug-resistance phenotype in chloroquine resistant Plasmodium falciparum (Guan et al. 
2002). In Leishmania spp, it was previously demonstrated that thioridazine, 
prochlorperazine, trifluoperazine, chlorpromazine and trifluoropromazine inhibit 
energy-dependant efflux of pirarubicin in resistant parasites from L. braziliensis, L. 
mexicana and L. guyanensis species (Essodaïgui et al. 1999).  
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II. Aims 
 
The general aim of the present study is to evaluate the action of efflux pumps in 
a context of P388D1 macrophages infected with Leishmania spp parasites previously 
exposed to conventional antileishmanial drugs, antileishmanial experimental 
compounds and efflux pump inhibitors. 
 
1. Specific aims 
 
2. To differentiate promastigotes of several different strains of Leishmania spp 
more resistant to commercial antileishmanial drugs and experimental 
antileishmanial compounds. 
3. To determine the antileishmanial effect of experimental compounds in several 
resistant Leishmania spp strains. 
4. To characterize the effect of the association of antileishmanial compounds with 
efflux pump inhibitors (EPI) in a context of macrophage (P388D1) infection by 
more resistant Leishmania spp promastigotes. 
 
 
 
 
 
 
 
 
 
 
 
   
1 
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III. Materials and methods 
 
1. Parasites 
 
1.1 - Culture of Leishmania promastigotes 
Promastigotes were cultivated in Schneider’s Insect Medium (SCHN, Sigma 
Aldrich) with L-glutamine, supplemented with 10% (v/v) Fetal Bovine Serum (FBS, 
Biowest), 100 μg.mL-1 of streptomycin (Sigma-Aldrich) and 100 U.mL-1 of penicillin 
(Sigma-Aldrich) and pH 7.2. The cultures were maintained at 24 ºC. The strains referred 
below were used in this work. 
 
1.2 - Leishmania (L.) infantum 
L. infantum (MCAN/PT/2012/IMT0005SG) was obtained from a canine 
leishmaniasis case in the municipality of Seixal, Setúbal, Portugal and maintained in 
BALB/c mice. Virulent promastigotes were isolated from the spleen of the infected 
mice and inoculated into the culture medium. These promastigotes were maintained in 
culture until four passages in order to retain their virulence. 
 
1.3 - Leishmania (L.) amazonensis 
In this work were used two different strains of L. amazonensis: 
HOM⁄BR⁄1973⁄M2269 e IFLA/BR/67/PH8. 
The strain HOM (MHOM⁄BR⁄1973⁄M2269) was isolated from a patient with 
American tegumentary leishmaniasis in the state of Pará, Brazil. It was classified by 
monoclonal antibodies and isoenzymes in Evandro Chagas Institute, Belém, State of 
Pará, Brazil. This strain was provided by Luiz Felipe Passero, from Laboratório de 
Patologia de Moléstias Infeciosas, Faculdade de Medicina da Universidade de São 
Paulo, Brazil (LPMI-FMUSP). 
The strain PH (IFLA/BR/67/PH8) was isolated in a phlebotomine collected in 
the state of Pará, Brazil. It was classified by isoenzymes in Evandro Chagas Institute, 
Belém, State of Pará, Brazil. This strain was provided by Liliane Rocha, from the 
Laboratório de Leishmaniose e Doença de Chagas, Instituto Nacional de Pesquisas da 
Amazónia, Manaus, Brazil (LLDC-INPA). 
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1.4 - Leishmania (V.) shawi 
 This strain (MHOM/BR/96/M15789) was isolated from an individual with 
cutaneous leishmaniasis in Buriticupu, State of Maranhão, Brazil. These parasites were 
maintained in BALB/c mice footpad and then isolated. This strain was classified 
monoclonal antibodies and isozenzymes in Evandro Chagas Institute, Belém, State of 
Pará, Brazil. This strain was provided by Luiz Felipe Passero, from Laboratório de 
Patologia de Moléstias Infeciosas, Faculdade de Medicina da Universidade de São 
Paulo, Brazil (LPMI-FMUSP). 
 
1.5 - Leishmania (V.) guyanensis 
L. guyanensis (MHOM/BR/2001/M19663) from an individual with American 
tegumentary leishmaniasis in the state of Pará, Brazil. It was classified by isoenzymes in 
Evandro Chagas Institute, Belém, State of Pará, Brazil. This strain was provided by 
Luiz Felipe Passero, from Laboratório de Patologia de Moléstias Infeciosas, Faculdade 
de Medicina da Universidade de São Paulo, Brazil (LPMI-FMUSP). 
 
2. Cell line 
P388D1 is a mouse tumor cell-line, whose cells present macrophage-like 
characteristics (Koren et al, 1979).  
 This cell line was cultivated in RPMI (from Roswell Park Memorial Institute 
culture medium) 1640, (Lonza, Belgium) supplemented with 10 % (v/v) of heat-
inactivated FBS, 2 mM of L-glutamine (Merck, Germany), 50 U.mL-1 (Sigma-Aldrich) 
and 50 μg.mL-1 of streptomycin (Sigma-Aldrich). Macrophages were cultivated in 
suspension at 37ºC in a humidified atmosphere with 5% CO2.  
 
3. Promastigotes less susceptible to drugs and experimental compounds 
 
3.1 Exposing Leishmania promastigotes to drug pressure 
To obtain promastigotes more resistant to drugs, two different protocols were 
used: one  protocol were used to generate strains more resistant to Glucantime; the other 
to originate strains more resistant to miltefosine (MILT), ursolic acid (URS), chalcone-8 
(CH8) and quercetine (QC). 
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Five different species/strains of Leishmania were used: Leishmania infantum 
(four passages), Leishmania amazonensis HOM (eight passages), Leishmania 
amazonensis PH (eight passages), Leishmania shawi (eight passages), Leishmania 
guyanensis (eight passages). A solution of commercial Glucantime® (Merial, France) 
with 81 mg.ml-1 of meglumine antimoniate was used. The concentration of viable 
P388D1 cells in culture was determined in a Neubauer chamber, after dilution in a 
solution of Trypan Blue and adjusted to 2 × 106 cells/ml. Cellular suspension (150 
µl/well) was added to a 96-well microplate. Glucantime was added to each well in the 
concentration of 250 µg.ml-1. The microplate was incubated for 3 h at 37ºC and 5% 
CO2. After incubation, the concentration of viable P388D1 cells in each well was 
determined.  
Simultaneously, the concentration of promastigotes in each culture was 
determined in a Neubauer chamber, after dilution in a solution of RPMI/Glycerol (40%) 
and adjusted to the triple of P388D1 cells concentration. Leishmania suspension (50 
µl/well) was added to macrophages. The microplate was incubated for 72 h at 24°C. 
After this period, the content of each well was collected to a T-Flask and cultivated in 
Schneider medium with 10% of FBS. When the promastigote concentration in culture 
reached the initial concentration (determined before the assay), the protocol was 
repeated with the double of Glucantime concentration. This protocol was used for 
because the mechanism of action of Glucantime that only works in the intracellular 
amastigote stage. So, it was used a model of infection with the promastigotes and 
P388D1. After culture in a T-flask, only the promastigotes that had left the macrophages 
exposed to Glucantime would grow in a culture medium containing Glucantime. 
A different protocol, adapted from (Mateus 2014) was differentiated 
peomastigotes under miltefosine (MILT), ursolic acid (URS), chalcone-8 (CH8) and 
quercetine (QC) drug pressure. The following solutions were used: solution of 
commercial Milteforan® (Virbac, France) with miltefosine (20 mg.ml-1); ursolic acid 
diluted in DMSO (4 mg.ml-1), chalcone-8 diluted in DMSO (0.5 mg.ml-1) and quercetin 
diluted in DMSO (9 mg.ml-1). The strains used were L. infantum (four passages), L.  
amazonensis HOM, L. amazonensis PH, L. shawi and L.  guyanensis (twelve passages). 
The IC50 values considered in this work were those referred in Fernandes (2013). High 
IC50 values were excluded and the compounds used for each species/strain are therefore 
mentioned as: L. infantum: miltefosine (INF MILT), ursolic acid (INF URS), chalcone-
8 (INF CH8) and quercetine (INF QC); L. amazonensis HOM: miltefosine (HOM 
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MILT) and quercetine (HOM QC); L. amazonensis PH: miltefosine (PH MILT), ursolic 
acid (PH URS), chalcone-8 (PH CH8) and quercetin (PH QC); L. shawi: miltefosine 
(SHAW MILT), ursolic acid (SHAW URS) and chalcone- 8 (SHAW CH8); L. 
guyanensis: miltefosine (GUYA MILT) and ursolic acid (GUYA URS). 
For each strain/compound, eight two-fold dilutions were made in a 96-well plate. 
Replicated three times. In parallel negative controls were made in independent wells 
without compound addition. 
The concentration of each Leishmania culture was determined through direct 
counting in a Neubauer chamber, after dilution in a solution of RPMI/Glycerol (40%) 
and adjusted to 2 × 106 promastigotes/ml. In each well containing the drug dilutions, 
100 μl of adjusted Leishmania culture were added. Then, the plates were sealed and 
incubated for 96 h at 24 °C. 
After the period of incubation, the plates were examined by optical microscopy 
and each well was considered positive or negative according to the presence of live 
promastigotes or not. The highest dilution in which was possible to find live 
promastigotes was collected and centrifuged at 130 ×g for 10 min to remove the dead 
parasites in the medium. The supernatant obtained was centrifuged three times at 1800 
×g for 10 min in sterile saline solution and suspended in complete SCHN medium. The 
culture was maintained until promastigote concentration reached 2 × 106 
promastigotes/ml, where the experiment was repeated. The assay was executed until the 
drug concentration of the highest dilution in which are present live promastigotes was 
four times the highest dilution in the first assay (the dilution at the end in which it is 
possible to find live parasites would be lower than the dilution at the beginning, which 
means that a higher concentration of compound is needed to kill the same concentration 
of parasite). 
 
3.2 - Exposing promastigotes to the drug pressure of miltefosine (MILT), ursolic 
acid (URS), chalcone-8 (CH8) and quercetine (QC) in T-flask culture 
The same compounds and the same Leishmania strains that are above referred 
were used in this assay. The concentration of each culture were determined through 
direct counting in a Neubauer chamber, after dilution in a solution of RPMI/Glycerol 
(40%) and adjusted to 2 × 106 promastigotes/ml.   
In the first round of the experiment, SCHN medium (3ml) present in all cultures 
contained twice the IC50 value according to the compound/species or strain considered 
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and  the DMSO (v/v) were lower than 1%. After the promastigote concentration reached 
the initial concentration (2 ×106 promastigotes/ml), the cultures were centrifuged at 130 
×g during 10 min to remove the dead parasites. Parasite concentration of each culture 
were determined through direct counting in a Neubauer chamber after dilution in a 
solution of RPMI/Glycerol (40%) and adjusted to 2 × 106 promastigotes/ml. The 
compounds were again added to each culture, but this time at a higher concentration 
than before (double IC50 concentration). The protocol was successively repeated, but 
doubling compound concentration in each round (4 times and 8 times the  IC50 value). 
After centrifugation at 1800 xg during 10 min, the pellet obtained for each 
culture was suspended in PBS and frozen at -80 ºC for later DNA extraction. 
 
4. IC50 of experimental compounds in more resistant promastigotes  
 
The IC50 values of ursolic acid, chalcone-8 and quercetine were determined for 
the more resistant Leishmania species, previously under drug pressure. The resazurin 
method that was used in this experiment was adapted from Vale-Costa et al. (2012) and 
Fernandes (2013). The concentration of promastigotes in all assays was previously 
adjusted to 5 × 105 promastigotes/ml. The concentrations of ursolic acid used ranged 
between 100 μg.ml-1 and 1.56 μg.ml-1 , concentrations of chalcone-8 between 10 μg.ml-1 
and 0.16 μg.ml-1 and concentrations of quercetin between 60 μg.ml-1 and 0.94 μg.ml-1. 
The essays were executed in black 96-well microplates (Thermo Fisher Scientific), 
designed for fluorescence-based assays. Promastigotes with the dilutions of the 
compounds were incubated for 24 h and then 1.25 mM resazurin/PBS was added to 
each well. The intensity of fluorescence was read after 4 h. The IC10 and IC50 for each 
species were determined in GraphPad. 
 
5. Determination of the effect of antileishmanial compounds combined with 
efflux pump inhibitors (EPI)  
 
5.1. Infection of P388D1 macrophages (MØ) with Leishmania promastigotes 
In a 24-well microplate, it was added a P388D1 macrophage suspension in 
RPMI 1640 supplemented with 10 % (v/v) of heat-inactivated FBS to each well. The 
concentration of the suspension was previously adjusted to 8 × 105 MØ/ml. More 
resistant Leishmania promastigotes of each species/strain previously developed were 
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added to each well in a proportion of 3:1. The process of incubation, executed at 37 ºC 
in a humid atmosphere with 5% of CO2 had different times according to the 
Leishmania species considered (Table 1). 
 
Species Incubation time (h) 
L. infantum 5 
L. amazonensis 48 
L. shawi 18 
L. guyanensis 18 
 
Table 1. Incubation times for the different Leishmania species 
 
5.2. Treatment of infected macrophages with antileishmanial compounds 
combined with EPI  
The concentration of infected macrophages in the previous stage were 
determined using the trypan blue exclusion method in a Neubauer chamber and then 
adjusted to 5 × 104 MØ/ml.  
The respective IC10 value of the EPI (verapamil, VER, sodium orthovanadate, 
ORT and Phe-Arg β-naphthylamide, PAβN) and the antileishmanial compound was 
added to each well. IC10 values for antileishmanial compounds were obtained in the 
previous section. IC10 values for EPI were based on results of Fernandes (2013) and can 
be consulted in Table 2. 
 
EPI Species 
 L. infantum L. amazonensis HOM L. amazonensis PH L. shawi L. guyanensis 
VER 1.966 1.966 1.966 1.966 1.966 
ORT 2.293 1.338 0.829 4.130 1.750 
PAβN 0.553 11.478 25.00 10.223 5-887 
 
Table 2. IC10 values of the EPI used in this work. All concentrations are expressed in μg.ml-1. 
 
 After this, the cells were incubated for 72 h at 37 ºC in a humid atmosphere with 
5% of CO2. 
For each assay, dilutions of non-treated infected macrophages were used as 
control. Other groups consisted in macrophages treated with the respective 
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antileishmanial compound, macrophages treated with the respective EPI and 
macrophages treated with both antileishmanial compounds and EPI. All samples were 
analyzed in triplicate in a total of three independent assays. 
 
5.3. Limit dilution assay (LDA) to determine the effect of the treatment in the 
infected macrophages 
After the incubation period, the content of each well was centrifuged at 1800 ×g 
for 10 min. The pellet was ressuspended in SCHN with 10% (v/v) FBS and the 
macrophage concentration was determined with optical microscopy and adjusted to 5 × 
104 MØ/ml. In a 96-well microplate, 200 µl of each suspension was added to the first 
well and then 8 serial dilutions of 1:4 were made. After 15 days of incubation, each well 
were observed for the presence or the absence of promastigotes. A well containing a 
single promastigote was considered positive and a well without any promastigotes 
negative. All the highest dilutions were compared to the control group to determine the 
relative percentage of cells that were effectively treated. 
 
5.4 Statistical analysis  
The statistical analysis was performed in GraphPad Prism 6. 
The control group was compared with the group of macrophages treated with 
antileishmanial compounds using a nonparametric Mann-Whitney test. A p-value < 0.05 
(95%) was considered indicative of statistically significant difference. 
The control group was compared with the group of macrophages treated with 
EPI and the group treated with EPI and antileishmanial compounds. For this purpose, it 
was performed a nonparametric Kruskal-Wallis test and a Dunn’s multiple comparisons 
test, with a statistical significance of 95 % (p < 0.05).  In the following Table 3 it is 
shown the notation used to represent the p-value in graphs. 
 
p value Notation Difference 
p value ≤ 0.05 * significant 
p value ≤ 0.01 ** Very significant 
p value ≤ 0.001 *** Extremely significant 
p value ≤ 0.0001 **** Extremely significant 
 
Table 3. Notation for the p-values obtained. 
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IV. Results 
 
1. Previous exposition to drugs lead to IC50 increases 
  
The values of IC50 and IC10 for each species/strain of the less susceptible 
promastigotes were determined and can be observed in Table 3. 
 
Species/strain IC50 (µg/mol) IC10 (µg/mol) 
INF URS 26.4 3.5 
INF CH8 3.4 0.8 
INF QC 37.7 17.2 
HOM QC 9.2 1.9 
PH URS 10.6 2.6 
PH CH8 5.4 1.5 
PH QC 4.8 1.1 
SHAW URS 8.3 1.3 
SHAW CH8 3.9 0.8 
GUY URS 37.5 11.5 
 
Table 4. IC50 and IC10  values for the various species/strains that were under drug 
pressure. 
 
 From the information on the table, it is possible to conclude that the strains INF 
CH8 and GUY URS presented the highest IC50 values, respectively 37.7 µg.mol
-1 and 
37.5 µg.mol-1. On the other hand, the strains SHAW CH8 and INF CH8 presented the 
lowest IC50 values, respectively 3.8 µg.mol
-1 and 3.4 µg.mol-1.  
 Comparing to the IC50 values previously obtained  for the wild type strains 
(Fernandes 2013) with the results obtained in the present study show that all strains that 
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were under drug pressure exhibite higher IC50 values, which is a good indicator of their 
resistance to the tested compounds. 
2. Effect of the treatment with antileishmanial compounds combined with EPI in 
infected macrophages 
 
2.1 – Treatments with URS combined with  VER, ORT or PAβN reduce the relative 
infection rate of INF URS 
The group treated with URS and the groups treated with different EPI (VER, 
ORT, PAβN) did not show any significant differences in the relative infection rate when 
compared to the control group (Fig.10A, B, C and D). The group simultaneously treated 
with URS and VER presented a significant reduction (13.3%) in the relative infection 
rate when compared with control (p = 0.0005, Fig. 10B). Both groups treated with URS 
plus ORT and URS plus PAβN presented significant reductions of the relative infection 
rate (p < 0.0001), respectively 15.0 % and 29.0 % (Fig.10C and D). 
 
 
 
  
 
 
 
    
 
 
 
 
 
 
 
 
Figure 10.  Effect of URS and EPI in macrophages infected with INF URS. The relative infection rate 
of infected MØ treated with URS (A), VER, URS + VER (B), ORT, URS + ORT (C), PAβN and URS + 
PAβN (D) was estimated through a dilution limit test. In parallel infected MØ (control) were also 
evaluated. The results are expressed by the mean and the standard deviation of three independent assays 
and of three replicates for each condition. *** and **** represent  extremely significant differences.  
*** 
 
B 
**** 
 
C 
**** 
 
D 
A 
   
33 
 
The results suggest that treatments with URS combined with the EPI  (VER, 
ORT or PAβN) reduces the relative infection rate of INF URS, probably by reducing 
drug efflux. 
 
2.2 – Treatments with CH8 in combination with VER, ORT or PAβN reduce the relative 
infection rate of INF CH8 
 Treatment of MØ with CH8 and with the  EPIs (VER, ORT, PAβN) did not 
reduce the relative infection rate (Fig. 11A). Treatment of INF CH8-infected MØ with 
CH8 in combination with VER reduced significantly (p = 0.0210) the relative infection 
rate in 7.5% (Fig.11B). When the groups were treated with CH8 plus ORT (Fig. 11C) 
and CH8 plus PAβN (Fig. 11D) the reduction of parasitized cells was extremely 
significant, respectively 13.1% (p = 0.003) and 16.5% (p < 0.0001). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  Effect of CH8 and EPI in macrophages infected with INF CH8. The relative infection rate  
of macrophages treated with CH8 (A),  VER, CH8 + VER (B), ORT, CH8 + ORT (C), PAβN and CH8 + 
PAβN (D) was estimated through a dilution limit test. In parallel infected MØ (control) were also 
evaluated. The results are expressed by the mean and the standard deviation of three independent assays 
and of three replicates for each condition. * represents a significant difference,  *** and **** represent 
extremely significant differences. 
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B 
C D 
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 The results suggest that the treatments with CH8 in combination with VER, 
ORT or PAβN are able to reduce significantly the relative infection rate of INF CH8, 
possibly by interfering with the activity of cell transporters. 
 
2.3 - Treatments with QC in combination with VER, ORT or PAβN significantly reduce 
the relative infection rate of INF QC 
Treatments of INF QC infect macrophages  with QC in combination with EPIs 
(VER, ORT, PAβN) presented an extremely significant reduction in the relative 
infection rate of  infected macrophages of 16.6% (p < 0.0001, Fig. 12B), 13.8% (p < 
0.0001, Fig. 12C) and 9.7% (p = 0.0004, Fig. 12D). Whereas the monotherapy with QC  
(Fig. 12A) or EPI did not have a significant effect on the relative infection rate. 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.  Effect of QC and EPI in macrophages infected with INF QC. The relative infection rate of 
macrophages treated with QC (A), VER, QC + VER (B), ORT, QC + ORT (C), PAβN and QC + PAβN 
(D) was estimated through a dilution limit test. In parallel infected MØ (control) were also evaluated.  
The results are expressed by the mean and the standard deviation of three independent assays and of three 
replicates for each condition. **** represents extremely significant differences  
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The results suggest that the treatments with QC and VER, ORT or PAβN are 
able to reduce significantly the relative infection rate of macrophages infected with INF 
QC possibly by affecting cell pumps. 
  
2.4 – Treatments with QC  combined with VER or PAβN reduce the relative infection 
rate of HOM QC 
 
Treatments of infected macrophages with QC (Fig.13A) or VER (Fig. 13B), 
ORT (Fig. 13C) and PAβN (Fig. 13D) did not reduce the relative infection rate. 
Surprisingly, the treatment with QC combined with ORT also did not significantly 
reduce the relative infection rate. On the other hand, treatment with QC plus VER lead 
to a high significant reduction (p = 0.0017) in the relative infection rate (10.0%) 
whereas treatment with QC combined with PAβN lead to an extremely significant 
reduction of the relative infection rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.  Effect of QC and EPI in macrophages infected with HOM QC. The relative infection rate 
of macrophages treated with QC (A), VER,  QC + VER (B), ORT, QC + ORT (C), PAβN and QC + 
PAβN (D) was estimated through a dilution limit test. In parallel infected MØ (control) were also 
evaluated. The results are expressed by the mean and the standard deviation of three independent assays 
and of three replicates for each condition. ** represents a very significant difference and **** represents 
an extremely significant difference. 
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The results suggest that the treatments with QC combined with VER or PAβN 
are able to reduce significantly the relative infection rate of macrophages infected with 
HOM QC, suggesting an important role of VER and PAβN in avoiding drug efflux. 
 
2.5 – Treatments with URS combined with VER or PAβN reduce the relative infection 
rate of PH URS 
PH URS infected MØ treated with URS associated with VER (Fig. 14B)  and 
URS combined with PAβN (Fig. 14D) showed very significant reductions in the relative 
infection rate of 6.9% (p = 0.0058) and 9.3% (p = 0.0012), respectively. Treatment with 
URS combined with ORT (Fig. 14C),  with EPI (VER, ORT, PAβN) or with URS  (Fig. 
14A) did not have a significant effect in infected macrophages.  
 
 
 
 
 
 
 
 
 
  
 
 
l 
  
 
 
 
Figure 14.  Effect of URS and EPI in macrophages infected with PH URS. The relative infection rate 
of macrophages treated with URS (A), VER, URS + VER (B), ORT, URS + ORT (C),  PAβN and URS + 
PAβN (D) was estimated through a dilution limit test. In parallel infected MØ (control) were also 
evaluated. The results are expressed by the mean and the standard deviation of three independent assays 
and of three replicates for each condition. ** represents very significant differences.  
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The results show that treatments with URS and VER or PAβN significantly 
reduce the relative infection rate of macrophages infected with PH URS. Also in this 
case VER or PAβN seem to have a decisive role in controlling drug efflux. 
 
2.6 –CH8  reduces the relative infection rate of PH CH8 
 
PHCH8 infected MØ treated  with CH8 in monotherapy  presented an extremely 
significant reduction (p = 0.0004) of the relative infection rate of 22.8% (Fig 15A). A 
similar reduction (22.6%) was also evidenced by infected MØ treated with CH8 in 
combination with PAβN (p = 0.0001, Fig. 15D). Treatment with CH8 combined with 
VER led to a very significant reduction of 10.0% (p = 0.0073). On the opposite side, the 
infected macrophages treated with CH8 and ORT and exclusively with each EPI (VER, 
ORT, PAβN) did not exhibit significant differences in infection levels. 
 
   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Figure 15.  Effect of CH8 and EPI in macrophages infected with PH CH8. The relative infection rate 
of macrophages treated with CH8 (A), VER, CH8 + VER (B), ORT, CH8 + ORT (C), PAβN,  CH8 + 
PAβN (D) was estimated through a dilution limit test. In parallel infected MØ (control) were also 
evaluated. The results are expressed by the mean and the standard deviation of three independent assays 
and of three replicates for each condition. ** represents a very significant difference and *** represents 
extremely significant differences. 
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 Although CH8 in combination with  VER or PAβN significantly reduce the 
relative infection rate of macrophages infected with PH CH8, the drug alone presents a 
similar effect. In this case, the effect of EPI seems to be disregarded. 
 
2.7 – Treatments with QC combined with  VER or PAβN reduce the relative infection 
rate of PH QC 
 The treatment of PH QC-infected macrophages with QC combined with VER 
led to a very significant reduction of 8.3% (p = 0.0058) in the relative infection rate 
(Fig. 16B) However, the treatment with QC plus PAβN (Fig.16D) caused an extremely 
significant reduction of 27.4% (p < 0.0001). The exclusive treatment with QC  (Fig. 
16A), QC in combination with ORT  (Fig. 16C) or with EPI (VER, ORT and PAβN) did 
not affect the relative infection rate. 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 16.  Effect of QC and EPI in macrophages infected with PH QC. The relative infection rate of 
macrophages treated with QC (A), VER, QC + VER (B), ORT, QC + ORT (C), PAβN and QC + PAβN 
(D) was estimated through a dilution limit test (LDA). In parallel infected MØ (control) were also 
evaluated. The results are expressed by the mean and the standard deviation of three independent assays 
and of  three replicates for each condition. ** represents a very significant difference and **** an 
extremely significant difference. 
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 The results suggest that treatments with QC and VER or PAβN significantly 
reduce the relative infection rate of macrophages infected with PH QC, pointing 
towards the activity of these two EPI on pump activity. 
 
2.8 – Treatments with URS  in combination with  EPI  do not reduce the relative 
infection rate of SHAW URS  
The treatment of infected macrophages with URS  (Fig. 17A) or with EPI (VER, 
ORT and PAβN) in monoterapy did not cause a significant reduction of the infection 
levels. Unlike the expectations, none of  the EPI (Fig, 17B, C and D) in combination 
with URS caused parasite reduction. 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Figure 17.  Effect of URS and EPI in macrophages infected with SHAW URS. The relative infection 
rate macrophages treated with URS (A), VER, URS + VER (B), ORT,  URS + ORT (C), PAβN and URS 
+ PAβN (D) was estimated through a dilution limit test (LDA). In parallel infected MØ (control) were 
also evaluated.  The results are the mean and the standard deviation of three independent assays and of 
three replicate for each condition.  
 
In this case,  the use of EPI  does not  seem to have an effect on SHAW URS 
parasites, probably due to important changes in parasite cell transporters. 
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2.9 – Treatments with CH8 in combination with EPI do not reduce the relative infection 
rate of SHAW CH8 
 
 SHAW CH8 infected macrophages treated with CH8 in monoterapy or in 
combination with  EPI did not present parasite reduction (Fig.18). 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.  Effect of CH8 and EPI in macrophages infected with SHAW CH8. The relative infection 
rate of macrophages treated with CH8 (A), VER,  CH8 + VER (B), ORT,  CH8 + ORT (C),  PAβN,  CH8 
+ PAβN (D) was estimated through a dilution limit test (LDA). In parallel infected MØ (control) were 
also evaluated. The results are expressed by the mean and the standard deviation of three independent 
assays and of three replicates for each condition.  
 
 The results suggest  again that  the EPI used in the present study do not have a 
detectable effect on SHAW CH8 parasites,  probably  by not having effect on  drug 
transport.   
 
2.10 – Treatments with URS in combination with VER, ORT or PAβN do not  reduce the 
relative infection rate of GUYA URS 
   The relative infection rate of infected macrophages is virtually constant across 
all groups and the different treatments did not cause an important parasite reduction 
(Fig.19). 
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Figure 19.  Effect of URS and EPI in macrophages infected with GUYA URS. The relative infection 
rate of macrophages treated with URS (A), VER, URS + VER (B), ORT, URS + ORT (C), PAβN and 
URS + PAβN (D) was estimated through a dilution limit test (LDA). In parallel infected MØ (control) 
were also evaluated. The results are expressed by the mean and the standard deviation of three 
independent assays with of  three replicates for each condition.  
 
The results suggest that treatments with URS in combination with VER, ORT or 
PAβN do not reduce the relative infection rate of GUYA URS. In this case  the effect of 
EPI in parasite pumps seems to be disregarded. 
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V. Discussion 
 
Leishmaniasis has a substantial impact all around the world, especially in 
underdeveloped countries, there are millions of deaths every year but the drugs 
available to treat the disease are scarce and are continuously losing efficacy. This loss of 
efficacy occurs mainly because the surge of Leishmania strains resistant to the few 
commercial drugs, so new drugs or new alternatives of treatment are needed to contain 
the expansion of the disease and treat the existent cases. So, the work aiming the study 
of drug resistance acquires great significance in the development of new strategies to 
treat the disease, as Hefnawy and colleagues point out (Hefnawy et al. 2016). Despite 
this, there is little investment and investigation of alternative treatments for 
leishmaniasis. The present work tries to contribute to the overcoming of this 
disappointing scenario. 
 
In terms of drugs, Glucantime is more effective in the amastigote stage of 
Leishmania because it needs the thiol-dependant reductase (TDR1) of the parasite to 
reduce the Sb(v) to Sb(III), which is the active form of the drug (Denton et al. 2004). 
Miltefosine acts through the disruption of lipid metabolism (Dorlo et al. 2012b), 
chalcone acts through the disruption of the parasitic mithocondria (Zhai et al. 1995) and 
quercetin through the inhibition of parasitic topoisomerase and arginase (Mittra et al. 
2000; Da Silva et al. 2012). From this, it’s easy to conclude that the antileishmanial 
compounds need to cross the membrane of the parasite and stay in its interior to execute 
their function. The reason why the efflux bombs are so important is because they export 
the compounds to the outside environment, impairing the function of these drugs and so 
the parasite can thrive even in their presence. The family of ABC transporters are 
largely responsible for the surge of chemoresistance phenotypes, not only in Leishmania 
parasites (Callahan and Beverley. 1991; Henderson et al. 1992; Katakura et al. 2004; 
BoseDasgupta et al. 2008; Coelho et al. 2008), but also in other parasitic organisms, as 
is the case of the helminth Schistosoma mansoni (Pinto-Almeida et al. 2015). Besides 
this, the efflux bombs are associated with antibiotic resistance (Lomovskaya et al. 
2001).  
 
According to Ubeda and coworkers, the genetic mechanisms involved in drug 
resistance in L. major, genes that encode for transporter proteins and others, are mainly 
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gene deletion, the formation of extrachromosomal linear or circular amplicons and 
aneuploidy, especially with the addition of extrachromosomes (Ubeda et al. 2008).  
 
The strains exposed to drug pressure in this work probably have enhanced efflux 
pump activity, because the IC50 values for ursolic acid, chalcone and quercetine were 
higher than those observed for the same strains and species, but not resistant 
(Fernandes. 2013). As the activity of the efflux pumps gets higher, less drugs will 
remain inside the parasite and less quantity of drug will be available at its site of action. 
The overall efficacy of the drug diminishes and the survival of the parasites rises. This 
is an experimental model for what occurs in field resistant-strains, where the activity of 
efflux pumps impairs the action of the drugs. 
 
One of the mains limitations of the current work lies in the uncertainty about the 
real resistance to antileishmanial compounds of the promastigotes used in the assays. 
For a matter of convenience, the term “more resistant” strains is used to define the 
strains obtained after drug exposure. Because of this, the natural next step of this work 
would be to look carefully at the expression levels or the mutations of the resistance 
genes of the Leishmania spp promastigotes, such as the following ones: pyridoxal 
kinase (PK) gene, whose mutations are related with appearance of miltefosine resistance 
in L. major promastigotes (Coelho et al. 2012); Ltr ABC1.1 and LtrABC2, whose 
overexpression are associated with antimoniate resistance (Katakura et al. 2004. Araújo-
Santos et al. 2005); PRP1 and MRPA, whose overexpression are presumably 
responsible for the decrease of influx of antimony in Leishmania spp parasites 
(Ashutosh et al. 2007).  
 
It has been demonstrated that ursolic acid increases nitric oxide production in 
macrophages (Passero et al. 2011), which leads to the programmed cell death of 
Leishmania parasites (Yamamoto et al. 2014). This compound has shown good 
antileishmanial activity, for example, in reducing the parasite burden in the spleen and 
the liver of infected hamsters (Jesus et al. 2017). The association of URS with VER, 
ORT or PAβN seems to be a good way to make the drug more available inside the 
parasite, so it can be a promising chemotherapeutic agent in the future. 
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Transporter proteins that belongs to ABC family are present, not only in the 
parasitic membrane, but also in the membrane of the macrophage cells. So, the action of 
the experimental leishmanicidal compounds used in this work can be severely impaired 
by their acitvity. It’s in the overcome of this situation that the action of the EPI can be 
crucial. VER, for example, it’s responsible for P-glycoprotein inhibition in Leishmania 
parasites from several species (Essodaïgui et al. 1999) and for the MDR phenotype 
reversion in cells (Wu et al. 2014). ORT can revert the MDR phenotype in Enterecoccus 
faecalis (Lee et al. 2003). PAβN it has been used as efflux pump inhibitor in 
Escherichia coli cells (Ospina Barrero et al. 2014).  
 
Previously, the association of VER with Glucantime showed good perspectives 
in in vitro isolates of L. donovani, through the reversion of the resistance phenotype 
(Valiathan et al. 2006) and in L. tropica parasites (Shokri et al. 2012). In this work, 
VER showed that can be administered with antileishmanial compounds, URS, CH8 and 
QC and can actively increase the efficacy of the drug, reducing the levels of 
macrophage infection by L. infantum and L. amazonensis. VER is a calcium channel 
blocker, so can impair the activity of these kind of efflux pumps of the parasite, and 
probably of the macrophage, making possible that the drug is not extruded by the 
parasite or even the macrophage cell. However, it could be the case that, in the infection 
model that was used, some parasites that appeared in the highest dilution could be 
outside the macrophages and not be able to enter them, so the combined treatment of the 
drug with the EPI wouldn’t have a direct effect in infection of macrophages. Further 
works with these compounds need to be done to reassure the efficacy of the treatment. 
 
ORT can significantly reduce infections levels of the macrophages infected with 
L. infantum, but seems to have no effect in other species, like L. amazonensis, L. shawi 
and L. guyanensis. 
 
PAβN can affect the efflux pump activity and increase the availability of 
antileishmanial drugs inside the parasite, which corroborates some previous results 
(Fernandes. 2013). It was the most effective EPI in all species tested. 
 
Since these EPI have little cytotoxicity in macrophage cells and can actively 
inhibit the activity of the efflux pumps, the use of these compounds simultaneously with 
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antileishmanial drugs can be an interesting option. The combined treatment with 
antileishmanial compounds and EPI can effectively reduce the parasitic burden in 
infected macrophages comparing to monoterapy with antileishmanial compounds. Even 
so,  PAβN does not have a detectable effect on resistant  L. shawi and L.  guyanensis 
parasites, which can be caused by alterations in the expression of the efflux pumps. In 
these more resistant strains obtained, the amount of ABC transporters present in the 
parasitic membrane  can be higher than the normal in non resistant strains and so the 
EPI can’t affect the activity of all efflux pumps. In the opposite, if these transporters 
aren’t present in the membrane, the EPI will not have any target to act. 
 
Unlike the initial expectations, it was not possible to test the efficacy of the 
association of the EPI with some conventional leishmanicidal drugs, like Miltefosine 
and Glucantime. All the essays made in order to obtain susceptible promastigotes to 
these compounds failed. In the case of Glucantime, the main reason is the excessive 
drug concentration needed to induce the susceptibility in the promastigotes and the lack 
of resistance presented after successive rounds of exposure to very high concentrations 
of this compound. Despite evidence that it is possible to obtain miltefosine-resistant 
strains of L. infantum (Mateus. 2014), it was not possible to obtain the same outcome in 
the present work, being the reason unknown. Maybe for future works, the protocol can 
be changed and new ways of inducing resistance in promastigotes can be tested. It 
would be important to test the association of these commercially available drugs with 
the EPI, since these two drugs are the ones the public gets access to, whereas the 
antileishmanial compounds used (URS, CH8 and QC) are only experimental and might 
never reach the commercialization phase. 
 
Another limitation of the present work it’s the fact that all assays were made in 
vitro. It’s more difficult to extract conclusions about the real efficacy of this strategy of 
treatment if the results are not complemented by a set of results obtained from in vivo 
experimental models. As so, one of the future directions this work could take would be 
to overcome this limitation by executing an array of in vivo assays using, for example, 
hamsters as experimental model.  Additionally, other Leishmania species than those 
used in this work can be tested to evaluate the potential of treatment using this new 
strategy. 
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VI. Conclusions 
 
The association of VER and PAβN with the experimental antileishmanial 
compounds URS, CH8 and QC can impair the efflux activity of ABC transporters (both 
the efflux pumps of the parasite and the macrophage probably), while increasing the 
availability of the compounds inside the parasites belonging to L. infantum and L. 
amazonensis species. ORT is only effective in the treatment of macrophages infected 
with L.infantum. PAβN is the most effective EPI and ORT the less effective. 
 
On the opposite side, the strategy of combining the experimental antileishmanial 
compounds with EPI seems to be ineffective in macrophages infected with different 
strains belonging to L. shawi and L. guyanensis species, which can be explained by 
alterations in the expression of the efflux pumps in these species. These alterations in 
the target of the EPI can lead to a loss of efficacy of these compounds. 
 
The positive results open possibilities to execute the strategy of combining 
antileishmanial compounds with EPI for the treatment of leishmaniasis, but using 
different antileishmanial compounds, especially conventional drugs, other Leishmania 
species and other resistant strains. The EPI have a significant impact in the decrease of 
efflux pumps activity and increase of the efficacy of antileishmanial drugs. 
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